CD274 and neoplasm: In the KEYNOTE-001 study, NSCLC patients whose tumors expressed PD-L1, as assessed by immunohistochemistry, in >50% of the tumor cells had better response rates to pembrolizumab than patients with lower PD-L1 expression levels [128].